Our exclusive poll captures today's top trends and perspectives—shaped by those pharma decision-makers impacted the most.

With COVID-19 subsiding and the public health emergency over, most people no longer dwell on the virus that so recently terrified the world. Yet millions are still forced to do so because of ...

IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to ...

US President Donald Trump has resurrected a drug pricing plan that equates to International Reference Pricing.

Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 DeficiencyFirst Pivotal Data Readout in Children ...

Windtree Therapeutics, Inc. ("Windtree” or "the Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative ...

RedChip Companies will air interviews with BioVie Inc. (NASDAQ:BIVI) and Liberty Star Minerals (OTCQB:LBSR) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this ...

BioMarin Pharmaceutical Inc. and Inozyme Pharma, Inc. announced today that BioMarin has entered into a definitive agreement to acquire Inozyme for $4.00 per share in an all-cash transaction for a ...

STAAR Surgical Company , the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICLtm) for vision correction, today announced that its Board of Directors has ...

Stem cell injections, platelet rich plasma and ivermectin do big business despite dubious or no evidence supporting their use in rheumatology. However, far from being a recent development, this type ...

Conference call begins at 10:00 a.m. Eastern time on Friday, May 16, 2025 WOBURN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company sp ...

Artificial Intelligence (AI) is now used throughout clinical trials, from recruitment to analysis – but are regulators ...